US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alk Abello AS

28.95

0.0000

Volume:- -

Turnover:- -

Market Cap:6.40B

PE:77.78

High:28.95

Open:28.95

Low:28.95

Close:28.95

52wk High:30.53

52wk Low:19.90

Shares:221.19M

Float Shares:131.39M

Volume Ratio:0.05

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.3722

EPS(LYR):0.3259

ROE:18.56%

ROA:11.11%

PB:7.44

PE(LYR):88.83

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ALK enters into neffy® co-promotion agreement in the USA

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

ITULAZAX® tree pollen tablet approved for treatment of children in Europe

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AKBLF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AKBLF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AKBLF\",,,,,undefined,":{"symbol":"AKBLF","market":"US","secType":"STK","nameCN":"Alk Abello AS","latestPrice":28.95,"timestamp":1756497600000,"preClose":28.95,"halted":0,"volume":0,"delay":15,"floatShares":131392384,"shares":221189247,"eps":0.372211,"marketStatus":"Closed Labor Day","change":0,"latestTime":"08-29 16:00:00 EDT Delay","open":28.95,"high":28.95,"low":28.95,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.372211,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1756800000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":28.95,"volumeRatio":0.05208308919385274},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AKBLF\",,,,,undefined,":{"symbol":"AKBLF","floatShares":131392384,"roa":"11.11%","roe":"18.56%","lyrEps":0.325905,"volumeRatio":0.05208308919385274,"shares":221189247,"dividePrice":0,"high":28.95,"amplitude":0,"preClose":28.95,"low":28.95,"week52Low":19.9,"pbRate":"7.44","psRate":"7.42","week52High":30.525,"institutionHeld":0,"latestPrice":28.95,"eps":0.372211,"divideRate":0,"volume":0,"delay":15,"ttmEps":0.372211,"open":28.95,"prevYearClose":22.35,"prevWeekClose":28.95,"prevMonthClose":28.95,"prevQuarterClose":27.65,"fiveDayClose":28.95,"twentyDayClose":28.95,"sixtyDayClose":26.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AKBLF\",params:#limit:5,,,undefined,":[{"date":"2024-05-02","symbol":"AKBLF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714636800000,"name":null,"time":"Pre-Market","dateTimestamp":1714622400000,"actualEps":null},{"date":"2022-11-10","symbol":"AKBLF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668070800000,"name":null,"time":"Pre-Market","dateTimestamp":1668056400000,"actualEps":null},{"market":"US","date":"2022-08-11","symbol":"AKBLF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1660190400000,"reportTimeType":"","actualEps":null},{"date":"2022-05-12","symbol":"AKBLF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1652342400000,"name":null,"time":"","dateTimestamp":1652328000000,"actualEps":null},{"market":"US","date":"2022-03-28","symbol":"AKBLF","defaultRemindTime":1648474200000,"type":"split","dateTimestamp":1648440000000,"forFactor":1,"toFactor":20,"ratio":0.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AKBLF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AKBLF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AKBLF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532481668","title":"ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians","url":"https://stock-news.laohu8.com/highlight/detail?id=2532481668","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532481668?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States. New partnership expands ARS Pharma’s direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatricians ahead of the back-to-school season. “As a result of broad coverage from leading pharmaceutical benefit managers and health plans, millions of patients nationwide now have improved access to neffy,” said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. “This partnership extension with ALK allows us to efficiently reach healthcare professionals who represent about 55% of all community-use epinephrine prescriptions in the United States. By expanding direct promotion with ALK, the global leader in allergy immunotherapy  with substantial experience in the allergy space, we ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-announces-co-promotion-120000254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1878469433.USD","BK4104","BK4007","BK4585","LU0053671581.USD","AKBLF","SPRY","BK4500","LU0054578231.USD","AIT","ALK","BK4008","BK4588","LU2065731478.USD"],"gpt_icon":0},{"id":"2532184819","title":"ALK enters into neffy® co-promotion agreement in the USA","url":"https://stock-news.laohu8.com/highlight/detail?id=2532184819","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532184819?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:59","pubTimestamp":1746187140,"startTime":"0","endTime":"0","summary":"Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way.Agreement does not change ALK’s revenue and earnings outlook for 2025.ALK  today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc.  to co-promote the neffy adrenaline  nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close to 10% of all adrenaline auto-injector prescriptions in the USA.Commenting on the new agreement, ALK's CEO Peter Halling said: “We are excited about expanding our partnership with ARS Pharma, which we firmly consider a win-win situation for all parties. More children, caregivers, and prescribers in the USA get access to an effective and needle-free anaphylaxis treatment. Although the agreement initially will have a limited financial impact for ALK, we are strengthening our capabilities in the USA. This may also support our respir","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alk-enters-neffy-co-promotion-115900482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKBLF","BK4585","BK4500","BK4139","EBIT","SPRY","BK4588","BK4008","ALK","BK4007"],"gpt_icon":0},{"id":"2531433752","title":"Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531433752","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531433752?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:39","pubTimestamp":1745937540,"startTime":"0","endTime":"0","summary":"ALK  will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025.Later on the same day, the company will host a presentation for investors and analysts at 11:00 a.m. CEST, where ALK’s management will comment on the results and outlook and be available for questions.ALK will be represented by Peter Halling, President & CEO, Claus Steensen Slje, CFO and Per Plotnikof, VP, Head of IR.The meeting will be audio webcasted live and be available for replay on ALK’s website.The presentation will be available on ALK's website shortly before the meeting starts.Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525. About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hrsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invitation-presentation-alk-first-quarter-143900393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4500","ALK","AKBLF","BK4585","BK4008","BK4588"],"gpt_icon":0},{"id":"2529682357","title":"ITULAZAX® tree pollen tablet approved for treatment of children in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2529682357","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529682357?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:58","pubTimestamp":1745416680,"startTime":"0","endTime":"0","summary":"ALK  today announced that its European regulatory filing for ITULAZAX  for treatment of young children and adolescents aged five to 17 has been approved by the health authorities in 17 EU countries via a type II variation procedure. First market introductions are expected to follow in the coming months ahead of the 2025/2026 initiation season for new patients starting treatment on pollen allergy tablets.Executive Vice President of R&D, Henriette Mersebach , says: “We are very pleased with the European health authorities' approval which allows us to provide this important treatment option to children and adolescents whose lives are impaired by uncontrolled tree pollen-induced respiratory allergy. Today’s approval marks another significant milestone in our continuous efforts to make our respiratory tablets available to all age groups in all relevant markets\".The tree tablet, branded ITULAZAX in Europe and ITULATEK in Canada, has, until now, been approved by 22 countries for adult patient","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/itulazax-tree-pollen-tablet-approved-135800319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4196","AKBLF","MD"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AKBLF\",params:#limit:6,delay:false,,,undefined,":[]}}